| Emerald Resources NL (EMR) ORDINARY FULLY PAID |
Materials |
$3,681 |
Quarterly Report
|
30 Jan 2026 9:12AM |
$8.000 |
$5.570 |
fallen by
30.38%
|
|
EMR - Price-sensitive ASX Announcement
Full Release
Key Points
- Emerald Resources NL reported significant progress at both its Okvau Gold Mine in Cambodia and Dingo Range Gold Project in Western Australia.
- The Okvau Gold Mine produced 25,030oz of gold during the quarter with an All-In Sustaining Cost (AISC) of US$1,032/oz.
- Emerald continues to pursue resource expansion at the Dingo Range Gold Project, with an updated Mineral Resource Estimate of 40.9Mt at 1.1g/t Au.
- The Memot Gold Project in Cambodia also saw progress with updated Indicated and Inferred Mineral Resource Estimates of 45.0Mt at 1.2g/t Au.
- Emerald has committed to sustaining its ESG initiatives, focusing on carbon neutrality and community engagement.
- The company supports significant community initiatives and infrastructure funding in Cambodia.
- The Dingo Range Gold Project has received all necessary approvals, and development and drilling activities are ongoing to further delineate resources.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Magmatic Resources Limited (MAG) ORDINARY FULLY PAID |
Materials |
$13 |
Quarterly Activities/Appendix 5B Cash Flow Report
|
30 Jan 2026 9:12AM |
$0.055 |
$0.025 |
fallen by
54.55%
|
|
MAG - Price-sensitive ASX Announcement
Full Release
Key Points
- A$3.5 million exploration budget for Myall Project with Fortescue.
- Completion of 25-hole aircore drilling program at Myall Project.
- Commencement of a 14-hole, 5,000-metre diamond drilling program.
- Cash position at end of quarter at A$6.2 million.
- Firm commitments for A$3.0 million placement.
- Significant focus on Northparkes-style copper-gold porphyry deposits.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| MRG Metals Limited (MRQ) ORDINARY FULLY PAID |
Materials |
$9 |
31 December 2025 Quarterly Activity & Cashflow Report
|
30 Jan 2026 9:12AM |
$0.005 |
$0.003 |
fallen by
40%
|
|
MRQ - Price-sensitive ASX Announcement
Full Release
Key Points
- Acquisition of Garies Rare Earth Project in South Africa.
- Introduction of experienced executives Jacob Deysel and Ian Egan.
- Transitioning to a diversified company with three core assets.
- Strong exploration results at Adriano–Fotinho Rare Earth Project in Mozambique.
- Heavy Mineral Sands Joint Venture backed by substantial JORC resource.
- Completion of $0.73 million capital raise.
- Strategic positioning for significant growth in 2026 with multiple milestones.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Nagambie Resources Limited (NAG) ORDINARY FULLY PAID |
Materials |
$11 |
Proposed Alkane and Nagambie Joint Venture
|
30 Jan 2026 9:12AM |
$0.010 |
$0.009 |
fallen by
10%
|
|
NAG - Price-sensitive ASX Announcement
Full Release
Key Points
- $27.5 million staged expenditure by Alkane to earn up to 80% interest, Nagambie retains 20%.
- Alternatively, $12.5 million expenditure by Alkane for 60% interest, Nagambie retains 40%.
- Formation of ANJV upon completion of the earn-in.
- Alkane to become a significant shareholder in Nagambie.
- Potential for significant future cash flow from ANJV antimony and gold production.
- Nagambie retains 100% of Whroo Mines and Wandean Projects.
- Synergies between Nagambie Mine and Alkane's Costerfield operations.
- Alkane provides access to its Costerfield Plant and equipment.
- Nagambie avoids major capital and operational costs for a new mine.
- Nagambie retains control over Whroo Mines Gold-Antimony Project and Wandean Gold-Antimony Project.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Alkane Resources Ltd (ALK) ORDINARY FULLY PAID |
Materials |
$1,981 |
NAG: Proposed Alkane and Nagambie Joint Venture
|
30 Jan 2026 9:12AM |
$1.670 |
$1.450 |
fallen by
13.17%
|
|
| Paradigm Biopharmaceuticals Limited (PAR) ORDINARY FULLY PAID |
Health Care |
$94 |
December 2025 Quarterly Activities Report & Appendix 4C
|
30 Jan 2026 9:11AM |
$0.315 |
$0.160 |
fallen by
49.21%
|
|
PAR - Price-sensitive ASX Announcement
Full Release
Key Points
- Phase 3 knee osteoarthritis trial PARA_OA_012 is actively recruiting in multiple countries.
- Additional clinical sites in Hong Kong and Moldova enhance global recruitment.
- Interim analysis of the trial expected by mid-2026.
- Cash balance at the end of the quarter stands at approximately A$14.66 million.
- Publication of Phase 2 biomarker study in a peer-reviewed journal.
- Strong funding position with available facilities of A$22.41 million.
- Continued engagement with NFL Alumni as part of recruitment efforts.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Jupiter Energy Limited (JPR) ORDINARY FULLY PAID |
Energy |
$32 |
Change of Director's Interest Notice
|
30 Jan 2026 9:11AM |
$0.025 |
$0.025 |
fallen by
0%
|
|
| AUB Group Limited (AUB) ORDINARY FULLY PAID |
Financials |
$3,698 |
AUB Key Investor Dates 2026
|
30 Jan 2026 9:11AM |
$30.300 |
$28.310 |
fallen by
6.57%
|
|
| Alpha HPA Limited (A4N) ORDINARY FULLY PAID |
Materials |
$1,002 |
Successful A$225M Capital Raising Supports Stage 2 Project
|
30 Jan 2026 9:11AM |
$0.845 |
$0.690 |
fallen by
18.34%
|
|
A4N - Price-sensitive ASX Announcement
Full Release
Key Points
- Successful A$225 million capital raising by Alpha HPA Limited.
- Funds to support Stage 2 HPA First Project construction and commercialisation.
- Significant demand from existing and new institutional investors.
- National Reconstruction Fund Corporation (NRFC) participated with A$75 million.
- Capital raising includes two tranches: A$105 million unconditional and A$120 million conditional.
- Complemented by a Share Purchase Plan for eligible shareholders.
- Government backing with existing funding lines up to A$704 million, including grants.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| IRIS Metals Limited (IR1) ORDINARY FULLY PAID |
Materials |
$17 |
Trading Halt
|
30 Jan 2026 9:10AM |
$0.195 |
$0.058 |
fallen by
70.26%
|
|
IR1 - Price-sensitive ASX Announcement
Full Release
Key Points
- IRIS Metals Limited requests trading halt due to capital raising program.
- Trading halt effective from 30 January 2026 until 3 February 2026 or announcement release.
- IRIS Metals focuses on critical minerals exploration in South Dakota, USA.
- Board of IRIS Metals approved the announcement.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Evion Group NL (EVG) ORDINARY FULLY PAID |
Materials |
$23 |
Maniry Permit approval advances as US pledge support
|
30 Jan 2026 9:09AM |
$0.028 |
$0.031 |
risen by
10.71%
|
|
EVG - Price-sensitive ASX Announcement
Full Release
Key Points
- Evion Group NL advances Maniry Graphite Project in Madagascar.
- Madagascan government expedites mining permit approvals.
- US and African Union launch Strategic Infrastructure and Investment Working Group.
- Madagascar recognized as a significant graphite exporter.
- Evion's Indian operations support global expansion with graphite exports.
- Evion holds EU Strategic Project status, enhancing permitting and stakeholder engagement.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Rural Funds Group (RFF) FULLY PAID UNITS STAPLED SECURITIES |
Real Estate |
$799 |
Update - Dividend/Distribution - RFF
|
30 Jan 2026 9:09AM |
$2.040 |
$2.050 |
risen by
0.49%
|
|
| Noxopharm Limited (NOX) ORDINARY FULLY PAID |
Health Care |
$29 |
December 2025 Quarterly Activities Report and Appendix 4C
|
30 Jan 2026 9:09AM |
$0.077 |
$0.093 |
risen by
20.78%
|
|
NOX - Price-sensitive ASX Announcement
Full Release
Key Points
- Completion of the HERACLES clinical trial with positive safety outcomes.
- New Material Transfer Agreement for developing therapeutic delivery systems.
- Recognition by Victorian Government for scientific collaborations.
- Preparation to start Phase II-enabling studies following trial success.
- Financial activities include securing a short-term loan and awaiting a tax rebate.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Beetaloo Energy Australia Limited (BTL) ORDINARY FULLY PAID |
Energy |
$377 |
Quarterly Activities Report - 31 December
|
30 Jan 2026 9:08AM |
$0.250 |
$0.250 |
fallen by
0%
|
|
BTL - Price-sensitive ASX Announcement
Full Release
Key Points
- NT Government approved Beetaloo Energy’s Beneficial Use of Gas application.
- Final Investment Decision (FID) on the Carpentaria Pilot Project achieved.
- First gas sales from EP187 expected in late 2026.
- Carpentaria Gas Plant construction commenced and progressing.
- Carpentaria-5H well showed strong flow rates and enhanced permeability.
- Total liquidity at the end of the quarter was $24.8 million.
- Funding expected to become available for continued project support.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| PainChek Ltd (PCK) ORDINARY FULLY PAID |
Health Care |
$20 |
Quarterly Activities/Appendix 4C Cash Flow Report
|
30 Jan 2026 9:07AM |
$0.270 |
$0.096 |
fallen by
64.44%
|
|
PCK - Price-sensitive ASX Announcement
Full Release
Key Points
- 115,073 contracted licenses globally in aged care facilities.
- Annual recurring revenue (ARR) of $5.6 million once fully implemented.
- Cash reserves of $4.8 million as of 31 December 2025.
- Customer receipts in the quarter were $810,000.
- FDA-regulated medical device status in the US for Remote Therapeutic Monitoring.
- Revised pricing strategy for Children’s and Infant App.
- Ongoing research and development to expand market reach.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| PainChek Ltd (PCK) ORDINARY FULLY PAID |
Health Care |
$20 |
PainChek Business Update
|
30 Jan 2026 9:07AM |
$0.270 |
$0.096 |
fallen by
64.44%
|
|
PCK - Price-sensitive ASX Announcement
Full Release
Key Points
- PainChek has achieved FDA De Novo clearance, allowing it to sell in the US market.
- PainChek's business model includes SaaS agreements and a new reimbursed model for RTM.
- There is a strong pipeline across the UK, ANZ, and North America with $1.9M ARR under negotiation.
- PainChek has 115,000 contracted licenses as of December 2025.
- The company has introduced a new tiered activation agreement with pre-payment options.
- PainChek Adult app has become the only FDA-cleared medical device for pain assessment in the USA.
- PainChek is positioned to benefit from RTM reimbursement codes, with a $3.05Bn total addressable market.
- The PainChek business model offers high gross margins over 80%.
- The company has conducted 17 million pain assessments across 200,000 residents globally.
- PainChek's future plans include launching an RTM business model in the US by March 2026.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Bougainville Copper Limited (BOC) 1 KINA ORDINARY FULLY PAID |
Materials |
$82 |
Company Update
|
30 Jan 2026 9:07AM |
$1.040 |
$0.205 |
fallen by
80.29%
|
|
BOC - Price-sensitive ASX Announcement
Full Release
Key Points
- BCL initiated a selection process for a mining partner in Q1 2025.
- Grant Samuel managed the strategic partnering process.
- CMOC Group Limited was chosen as the preferred mining partner in December 2025.
- ABG, the majority shareholder, did not support the CMOC partnership.
- ABG prefers Lloyd Metals & Energy Ltd. for the Panguna Mine redevelopment.
- BCL and CMOC are negotiating with ABG to gain support.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Oncosil Medical Limited (OSL) ORDINARY FULLY PAID |
Health Care |
$18 |
Trading Halt
|
30 Jan 2026 9:06AM |
$0.800 |
$0.585 |
fallen by
26.88%
|
|
OSL - Price-sensitive ASX Announcement
Full Release
Key Points
- OncoSil Medical Limited requested a trading halt.
- The halt is pending a capital raising announcement.
- The halt remains until the announcement or 3 February 2026.
- The company expects to announce before 3 February 2026.
- The request complies with ASX Listing Rule 17.1.
- The request was authorized by the Board of Directors.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Camplify Holdings Limited (CHL) ORDINARY FULLY PAID |
Industrials |
$16 |
Quarterly Activities/Appendix 4C Cash Flow Report
|
30 Jan 2026 9:06AM |
$0.450 |
$0.190 |
fallen by
57.78%
|
|
CHL - Price-sensitive ASX Announcement
Full Release
Key Points
- Operating cash flow for Q2 FY26 was $11.3 million.
- Receipts from customers during the quarter were $32.5 million.
- Operating expenses included $14.3 million for operating costs, $3.0 million for staff, and $2.9 million for administration.
- A $1.8 million accrual for unbudgeted insurance expenses was identified.
- CHL has no unused financing facilities at the end of the quarter.
- Cash balance at the end of the quarter was $23.2 million.
- Membership revenue growth was solid despite a decline in other revenue streams.
- The report was authorized by the Board of Directors of Camplify Holdings Limited.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Pentanet Limited (5GG) ORDINARY FULLY PAID |
Communication Services |
$6 |
Q2FY26 Appendix 4C
|
30 Jan 2026 9:05AM |
$0.033 |
$0.015 |
fallen by
54.55%
|
|
5GG - Price-sensitive ASX Announcement
Full Release
Key Points
- Pentanet Limited's report covers Q2FY26, ending December 2025.
- Net cash from operations was $710,000.
- Final payment made for 5G Spectrum license in 26 GHz band.
- Cash and cash equivalents at end of the period were $2,416,000.
- The report includes details on Pentanet's financing facilities.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Pentanet Limited (5GG) ORDINARY FULLY PAID |
Communication Services |
$6 |
Q2FY26 Quarterly Activities Report
|
30 Jan 2026 9:05AM |
$0.033 |
$0.015 |
fallen by
54.55%
|
|
5GG - Price-sensitive ASX Announcement
Full Release
Key Points
- Consolidated revenue increased 2% QoQ and 7% PcP to $6 million.
- Positive EBITDA of $0.4 million for the fifth consecutive quarter.
- Telecommunications revenue up 2% QoQ and 6% PcP to $5.4 million.
- 5G revenue increased by 11% QoQ and 330% PcP to $0.25 million.
- Gaming segment revenue up 3% QoQ and 7% PcP to $0.68 million.
- CloudGG ARPU increased 6% QoQ to $23.
- Net cash from operating activities improved 19% QoQ to $0.7 million.
- Implemented 'Nothing But Net' brand campaign to enhance market engagement.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Coles Group Limited (COL) ORDINARY FULLY PAID |
Consumer Staple |
$32,316 |
Advance Notice - 2026 Half Year Results
|
30 Jan 2026 9:04AM |
$21.050 |
$24.060 |
risen by
14.30%
|
|
| AUB Group Limited (AUB) ORDINARY FULLY PAID |
Financials |
$3,698 |
Application for quotation of securities - AUB
|
30 Jan 2026 9:04AM |
$30.300 |
$28.310 |
fallen by
6.57%
|
|
| Range International Limited (RAN) ORDINARY FULLY PAID |
Materials |
$3 |
Quarterly Activities/Appendix 4C Cash Flow Report
|
30 Jan 2026 9:04AM |
$0.004 |
$0.180 |
risen by
4,400%
|
|
RAN - Price-sensitive ASX Announcement
Full Release
Key Points
- Re>Pal Indonesia posts record sales revenue and production.
- Indonesian Q4 2025 sales revenue was US$737k.
- Re>Pal delivered 921 tonnes of pallets despite a 20-day production halt.
- Q4 2025 saw a 28% gross margin.
- Group cash burn was a net inflow of US$28k.
- Company relocating factory and seeking additional funding for rental fleet.
- Sales pipeline for Q1 2026 indicates strong customer support.
- Considering growth opportunities in Indonesia and the Philippines.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| EVE Health Group Limited (EVE) ORDINARY FULLY PAID |
Consumer Staple |
$7 |
EVE Completes Initial Production of Libbo
|
30 Jan 2026 9:04AM |
$0.020 |
$0.021 |
risen by
2.50%
|
|
EVE - Price-sensitive ASX Announcement
Full Release
Key Points
- Completion of initial production of Libbo™ oral dissolving film.
- Transition from development to commercial execution.
- Libbo™ targets erectile dysfunction with faster onset of action.
- Positioning for market entry through telehealth and pharmacy channels.
- Supports EVE’s strategy of commercializing innovative pharmaceutical solutions.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
Call 1300 880 160
Start a chat
Schedule a call
